Glaucoma News

NEW YORK — Nathan M. Radcliffe, MD, discusses combining MIGS and medication and the possibility of combining MIGS procedures in the future during his presentation at OSN New York 2019.

NEW YORK — During his presentation at OSN New York 2019, Thomas W. Samuelson, MD, discusses surgical treatment options for glaucoma and when each is ideal.

NEW YORK — In her presentation at OSN New York 2019, Valerie Trubnik, MD, FACS, discusses results of the LiGHT trial, which compared selective laser trabeculoplasty and eye drop treatment for mild to moderate glaucoma.

NEW YORK — During his presentation at OSN New York 2019, Robert J. Noecker, MD, MBA, discusses pharmacological treatment options for glaucoma, as well as cost and access issues.

NEW YORK — At OSN New York 2019, Joel S. Schuman, MD, FACS, discusses the use of OCT for glaucoma. Monitoring the ganglion cell layer, the nerve fiber layer and the visual field is important, especially in advanced glaucoma, he said.

Patients with elevated IOP due to either a fibrotic or shallow bleb or increased vascularity after Xen gel stent implantation experienced a mean 35.9% IOP reduction from preoperative levels after undergoing a needling revision, according to a study.

Ophthalmology’s armamentarium in the United States grew in 2019 with FDA approvals in retina and glaucoma treatment, as well as an approval for the first trifocal IOL.

As a new decade begins, Healio.com/OSN looks back at some of our biggest stories in the past 10 years. Over the years, ophthalmology has evolved to include new treatment options, both surgical and pharmaceutical, for numerous conditions affecting every part of the eye.

The European Medicines Agency has accepted and will review the marketing authorization application for Roclanda, Aerie Pharmaceuticals announced in a press release.

I did a quick survey and heard lots of terms used to describe the outer retinal lines as seen in OCT images.